Hyfe AI Expands its Scientific Advisory Board

Hyfe Inc. has added two new members to its Scientific Advisory Board to support its expansion into digital therapeutics  and behavioral cough suppression therapy.

George Savage, M.D., is a clinician, serial medical entrepreneur and investor with deep experience in digital therapeutics. He has successfully taken multiple ideas through the full lifecycle from conception to funding, development, regulatory approval, commercialization, and exit. He also co-founded Proteus Digital Health, a pioneer in obtaining U.S. Food and Drug Administration approval for integrated  drug-device combinations. In addition, Hyfe brought on Laurie Slovarp, Ph.D., CCC-SLP, a world leader in behavioral cough suppression therapy. Slovarp treats chronic cough in her clinic and leads National Institutes of Health-funded studies on cough hypersensitivity syndrome and cough suppression therapy. 
 
“Cough is one of the primary symptoms of any respiratory disease and at Hyfe we’re paving the way for patients and consumers to accurately track, understand and now treat their cough,” Hyfe AI Chief Medical Officer Dr. Peter Small said. “Savage and Slovarp’s expertise and addition to the Scientific Advisory Board positions Hyfe to bring a novel therapeutic modality to improve the lives of these underserved patients.”

The Scientific Advisory Board appointments coincide with the company’s plans to expand into chronic cough treatment with the world’s first digital therapeutic. The company has cracked the code on monitoring cough, gaining insights on ways to improve patients’ lives, and it is preparing to take the next step as an end-to-end cough company.
 
Hyfe is the leader in cough monitoring with more than 700 million sounds in its cough database. It can track and detect cough with 99%-plus accuracy on any mic-enabled device with no need for patient intervention while preserving patient privacy. The company is prepared to provide end-to-end care for cough sufferers. Using speech therapy to fix and suppress coughs, Hyfe is working on a digital therapeutic that will direct chronic sufferers with breathing exercises via their mobile device. Despite affecting about 10% of the general population, there has been no new cough medicine for more than 60 years. Used as a standalone treatment, or in combination with medicines, it offers hope to underserved patients. 
 
Hyfe Inc. develops AI-powered cough detection and classification technology that provides insight into cough patterns and correlations that can greatly improve treatment and prevention. With more than 700 million samples, Hyfe maintains the largest cough dataset in the world, enabling the building of powerful models to track, manage, and diagnose respiratory illnesses. Hyfe provides platforms and data for pharmaceutical companies, medical researchers, government agencies, healthcare providers, and patients and has partnerships with academic institutions including Johns Hopkins University and the University of California at San Francisco. The company was founded in 2020 and is headquartered in Wilmington, Del.